CANNTAB THERAPEUTICS LIMITED

MANAGEMENT DISCUSSION AND ANALYSIS

NINE MONTHS ENDED FEBRUARY 28, 2023 AND 2022

CANNTAB THERAPEUTICS LIMITED

MANAGEMENT DISCUSSION AND ANALYSIS
NINE MONTHS ENDED FEBRUARY 28, 2023 AND 2022

The following management discussion and analysis ("MD&A") of Canntab Therapeutics Limited ("Canntab" or "the Company") provides a review of corporate developments, results of operations and financial position for the three and nine months ended February 28, 2023 ("Q2 2023" and "YTD 2023" respectively) compared with the corresponding period ended February 28, 2022 ("Q2 2022"and "YTD 2022" respectively). This discussion is prepared as of April 26, 2023 and should be read in conjunction with (i) the unaudited interim condensed consolidated financial statements and the accompanying notes for the three and nine months ended February 28, 2023 and 2022, and (ii) both the audited consolidated financial statements and MD&A for the fiscal years ended May 31, 2022 and 2021. Additional information relating to the Company is available on Canntab's SEDAR profile at www.sedar.com and the Company's website at www.canntab.ca. The results reported in this MD&A have been prepared in accordance with International Financial Reporting Standards ("IFRS") and are presented in Canadian dollars, which is the Company's functional currency.

For the purposes of preparing this MD&A, management, in conjunction with the Board of Directors (the "Board"), considers the materiality of information. Information is considered material if: (i) such information results in, or would reasonably be expected to result in, a significant change in the market price or value of the Company's common shares, (ii) there is a substantial likelihood that a reasonable investor would consider it important in making an investment decision, or (iii) it would significantly alter the total mix of information available to investors. Management, in conjunction with the Board, evaluates materiality with reference to all relevant circumstances, including potential market sensitivity.

FORWARD-LOOKING STATEMENTS

This MD&A contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as "forward-looking statements"). These statements relate to future events or the Company's future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates" or "believes", or variations of, or the negatives of, such words and phrases, or statements that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those anticipated in such forward-looking statements. The forward-looking statements in this MD&A speak only as of the date of this MD&A or as of the date specified in such statement.

COMPANY OVERVIEW

Canntab Therapeutics Limited ("Canntab" or the "Company") was incorporated on April 20, 2016 under the Canada Business Corporations Act. The Company, with its head office located at 411 Cranbrooke Avenue, Toronto, Ontario, M4M 1N4 *(see discussion under "Premises Lease" section below)*, is a Canadian phytopharmaceutical company focused on the manufacturing and distribution of a full suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Long referred to as Cannabis 3.0 by the Company, Canntab's proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in pharmacies around the world. These include once a day and extended-release formulations, both providing an accurate dose and improved shelf stability.

CANNTAB THERAPEUTICS LIMITED

MANAGEMENT DISCUSSION AND ANALYSIS
NINE MONTHS ENDED FEBRUARY 28, 2023 AND 2022

Canntab trades on the Canadian Securities Exchange under the symbol "PILL" and the Frankfurt Stock Exchange under the symbol "TBF1". It previously traded on the OTCQB Best Market under the symbol "CTABF", but now trades under the same symbol on the OTC Pink Sheets.

In a currently declining economy and burdensome regulatory environment in Canada, it has become apparent that the emerging Canadian cannabis market by itself will take longer to fully adopt the Company's technology and products than its current financial resources will allow. Despite numerous agreements and/or marketing initiatives, sales at a commercially viable level in Canada have yet to materialize. Canntab previously held a Cannabis Standard Processing and Sales for Medical Purposes License and a Cannabis Research License from Health Canada. These licenses were surrendered in December, 2022. Under an agreement with a private licensed producer, the Company will conduct all its future cannabis processing and distribution activities under the private licensed producer's license with Health Canada. It is also undertaking efforts to license its technology internationally. Unless the Company can generate significant revenue from these efforts, it will be very difficult to continue operating as a going concern.

Canntab's business model has further expanded to explore the possibility/opportunity of licensing its patented technology to global cannabis manufacturers and other strategic parties. Canntab's intention is to license its proprietary technologies to other parties that will manufacture our tablet formulations in their respective jurisdictions. Canntab intends to transfer the technology and know-how to each licensed entity and discussions spanning several months are well underway with arm's length third parties in Europe and the United States. Management believes that it will close licensing agreements that will generate on-going royalty payments with several of these international partners.

CURRENT HIGHLIGHTS

- Vacated previous manufacturing and distribution premises at 223/225 Riviera Drive, Markham, Ontario when premises leases not renewed by landlord *(see further discussion under "Premises Lease" section below).*
- Voluntarily agreed to having Health Canada licenses revoked in December, 2022.
- On December 9, 2022, entered into an agreement with Black Rose Organics Canada Inc. ("BRO"), a private Ontario based licensed producer, to move its production, testing and manufacturing equipment to establish its tablet manufacturing process at another licensed facility in Canada *(see further discussion under "Agreement with Licensed Producer" section below).*
- Previous marketing and service agreements, including those signed with OnPharm-United, First Nations Growers GP Inc., Levitee Clinics Inc. and Pathway Health Corporation, have failed to yield any economic benefit to the Company. Management now considers them all to be effectively terminated, and is instead undertaking efforts to license the Company's technology internationally.
- In October, 2022, received first two orders from Nova Scotia Liquor Corporation.
- In October, 2022, IP Australia issued patent AU 2018233582 (Australian "Modified Release Multi-Layer Tablet Cannabinoid Formulations"), the Company's 4th granted patent and 2nd in Australia.
- In September, 2022, received agreement from holders of debentures subscribed for in December, 2020 to (i) extend the maturity date of the debentures from December 30, 2022 to October 31, 2023, and (ii) to forbear from declaring or acting upon, or exercising related rights or remedies, under the debentures.

RECENT EVENTS

Premises Lease

On November 17, 2022, the Company received a notice from their landlord that their lease for the Company's manufacturing facilities located at 223 Riviera Drive, Markham, Ontario, would not be renewed past its expiry date of December 31, 2022. The landlord also did not approve a sub-let of the premises at 225 Riviera Drive, Markham, Ontario, effectively requiring the Company to vacate those premises as well.

Health Canada Licenses

As a result of the cancellation of the premises lease, Canntab contacted Health Canada to engage in discussions to determine how Canntab may retain its various Cannabis licenses held by the Company. It was ultimately decided that the Company would voluntarily agree to having their Health Canada licenses revoked in December, 2022.

Agreement with Licensed Producer

As a consequence of the premises lease cancellation and revocation of its Health Canada licensing, management sought to move its production, testing and manufacturing equipment to establish its tablet manufacturing process at another licensed facility in Canada. On December 9, 2022, the Company entered into an agreement with Black Rose Organics Canada Inc. ("BRO"), a private Ontario based licensed producer, with the following major terms:

(i) Canntab has proprietary processes it has developed in order to manufacture cannabis-infused medical tablets products that it will provide;

(ii) BRO will provide necessary licenses to process cannabis products under the Cannabis Act and its regulations;

(iii) Canntab shall deliver and transfer to BRO its inventory of cannabis products (tablets and extracts) which BRO shall store at its licensed premises in Scarborough, Ontario, free of charge, to be repackaged by BRO, to manufacture or package tablets containing THC and/or CBD using Canntab's proprietary processes and equipment;

(iv) BRO will provide the facility for the installation of Canntab equipment (of which Canntab will still retain ownership), and BRO will manufacture cannabis-infused tablet products on the terms and conditions set out in the agreement;

(v) Canntab will during the term of this agreement allow BRO to use Canntab equipment to manufacture cannabis products for sale by BRO in accordance with the terms and provisions of the agreement;

(vi) Revenue will be shared as follows:

- As to Canntab's current inventory of packaged goods, 60% to Canntab and 40% to BRO;
- As to future production of Canntab products, 50% to Canntab and 50% to BRO;
- As to net profit from white label agreements brought from BRO by Canntab, 40% to Canntab and 60% to BRO.

All Canntab equipment and inventory was successfully moved to BRO's licensed facilities by the end of December, 2022. BRO is currently implementing the required steps to repackage the Canntab inventory and set up required business, legal and marketing procedures to sell that inventory into the jurisdictions that Canntab had been servicing.

Debenture Amending Agreement

On September 22, 2022, pursuant to the terms of the Interlender Agreement dated December 21, 2020, the Company entered into a Debenture Amending Agreement with the holders of the debentures issued on December 30, 2020 under which the parties agreed:

- to extend the maturity date of the debentures from December 30, 2022 (the "current maturity date") to October 31, 2023;
- to waive any default in payment due and payable as of the current maturity date and to forbear from enforcing any enforcement rights under the Interlender Agreement, or to forbear from declaring or acting upon, or exercising related rights or remedies under the debentures, relating to the current maturity date; and
- that all other terms of the debenture shall continue in full force and effect.

Convertible debentures

On January 31, 2022, the Company closed on its second private placement of $1,311,999 of secured debentures, issued at a price of $1,000 per debenture with a term of two years and due by January 31, 2024. The proceeds have been used to fund working capital for the Company and for general corporate purposes. Some of the major terms of the issuance, essentially similar to the first convertible debenture offering in December, 2020, are as follows:

(i) The principal amount bears interest at a rate of 10% per annum, payable quarterly in cash on the last business day of each calendar quarter. If the debenture holder elects, in its sole and absolute discretion, interest may be paid in common shares at the conversion price at any time following the issue date.

(ii) The debentures are convertible into common shares of the Company at a conversion price of $0.70 per share, and will mature two years from the date of issuance. Beginning on the date that is four months and one day following the closing date of the offering, the Company will have the right to prepay or redeem a part or the entire principal amount of the convertible debentures plus any accrued and unpaid interest at any time by providing a minimum of 20 days and a maximum 60 days of redemption notice prior to the redemption date. The conversion price will be subject to customary adjustments in certain events.

(iii) On closing, the Company issued to the purchasers of the convertible debentures one share purchase warrant for each share underlying the convertible debenture purchased, or 1,874,285 warrants in total. The warrants are exercisable for a period of two years from issuance into shares of the Company with each warrant entitling the holder thereof to acquire one share at an exercise price of $0.90 per share. The warrants are subject to an acceleration right exercisable by the Company at its option if, for the preceding 15 consecutive trading days, the volume weighted average trading price of the shares is greater than $1.05 per share. If the Company provides notice that it intends to exercise its acceleration right, the accelerated expiry date of the warrants will be the 30th calendar day following the date of such notice of exercise.

(iv) There are numerous other conditions with respect to conversion features, ratchet features and/or redemption privileges that caused the conversion feature and warrants to be classified as derivative liabilities and revalued each reporting period.

On September 22, 2022, pursuant to the terms of the Interlender Agreement dated December 21, 2020, the Company entered into a Debenture Amending Agreement with the holders of the debentures issued on December 30, 2020 *(see discussion under "Debenture Amending Agreement" section above)*.

GOING CONCERN

These unaudited interim condensed consolidated financial statements have been prepared on a going concern basis which assumes that the Company will, in the foreseeable future, continue to convert its sales orders into revenue, realize on its assets and discharge its liabilities in the normal course of business as they come due. Accordingly, the unaudited interim condensed consolidated financial statements do not give effect to adjustments that would be necessary should the Company be unable to continue as a going concern and, therefore be required to realize its assets and liquidate its liabilities and commitments in other than the normal course of business and at amounts different from those in these unaudited interim condensed consolidated financial statements. Such adjustments could be material.

As at February 28, 2023, the Company had an accumulated deficit of $18,610,663 (May 31, 2022 - $16,699,455). Working capital deficiency as at February 28, 2023 was $2,777,234 compared to $1,092,903 as at May 31, 2022. For the three months ended February 28, 2023, net loss and comprehensive loss was $412,628 (2021 - $1,911,208). Other than some initial licensing fees received and some recent online and international sales, operations since inception have been largely funded from the issuance of shares and convertible debentures, the exercise of stock options and warrants and the sale of excess equipment.

As a consequence of the premises lease cancellation *(see further discussion under "Premises Lease" section above)*.and revocation of its Health Canada licensing, management sought to move its production, testing and manufacturing equipment to establish its tablet manufacturing process at another licensed facility in Canada. On December 9, 2022, the Company entered into an agreement with Black Rose Organics Canada Inc. ("BRO"), a private Ontario based licensed producer *(see further discussion under "Agreement with Licensed Producer" section above)*. It is also undertaking efforts to license its technology internationally. Unless the Company can generate significant revenue from these efforts, it will be very difficult to continue operating as a going concern.

To continue as a going concern, the Company will also need to ii) obtain forbearance agreement from convertible debenture holders to forbear from enforcing their enforcement rights (as defined in the Interlender Agreement), or to forbear from declaring or acting upon, or exercising related rights or remedies under the debentures, (ii) arrange future financing that will largely depend upon prevailing capital market conditions and the continued support of its stakeholder base, and (iii) identify and negotiate partnerships to assist Canntab in expanding its product offerings in Canada, United States, and other international jurisdictions. However, there can be no assurance that management's plans will be successful. While the Company has been successful in prior fundraising efforts, there can be no assurance that (i) additional funds could be raised, or (ii) profitable operations can be achieved in the future. As a result, these factors indicate the existence of a material uncertainty that may cast significant doubt upon the Company's ability to continue as a going concern.

PRODUCTS

Under the terms of the BRO agreement *(see discussion under "Agreement with Licensed Producer" section above)*, Canntab is looking to sell and distribute its 12 Health Canada approved SKU's directly to every medically prescribed patient across the country. The Company is selling both THC and CBD tablets and caplets in a variety of doses in an Instant Release ("IR") format under the prescription name INSTACANN®.

The Company has developed the formulation and prototype for its next product, the Extended Release Tablet ("XR Tablet"), which delivers standardized medical cannabis extract from selective strains in a solid, extended release pharmaceutical dosage. In YTD 2023, the Company produced 2 commercial batches of 25 mg and 50 mg CBD tablets, the first of the XR product line. The Extended Release Tablet ("XR" or the "XR Tablet") is a proprietary phytocannabinoid vehicle that is designed to directly address the drawbacks and challenges of competing oral delivery systems. These challenges include, but are not limited to, accuracy of dosing, onset times, duration of action, bioavailability, discreetness of consumption, ease of spoilage and the reduction of side effects, and are all directly addressed by the unique formulation of the XR Tablet. The XR Tablet is designed to contain either THC, CBD or a combination of THC/CBD (depending on the composition of the medicine), permitting it to meet the demands of a broader patient base than the current synthetic-THC based pills in the market today.

In addition, Canntab has formulated an Oral Dissolvable THC Tablet ("ODT"). This tablet is intended to dissolve under one's tongue as opposed to swallowing the tablet as one does with both our IR and XR tablets and caplets. It actually breaks the brain barrier by being absorbed through an individual's buccal cavity. It boasts a 10 minute onset time on average and is the fastest cannabis delivery mechanism other than smoking or combusting cannabis. The intended targets for using these tablets are both the medical and "adult use" users.

The ODT and XR tablets will be available when production resumes later in calendar 2023. The XR tablets/caplets will come in the following strengths: (i) THC - 5mg and 10 mg, and (ii) CBD - 25 mg and 50 mg. The oral dissolvable THC tablets will come in 5mg.

INTELLECTUAL PROPERTY

The success of the Company's business depends in part on its ability to protect its technology and formulations related to pharmaceutical preparations containing natural or synthetic cannabinoids. In recognition of this, the Company continues to expand its intellectual property portfolio, which includes patent and trademark applications in the United States and Canada. On September 21, 2020, the Company announced it had been awarded a US patent titled "Modified Release Multi-Layer Tablet Cannabinoid Formulations" *(see discussion under "Recent Events" section above)*. The Company's intellectual property portfolio includes numerous patent applications in Canada, the United States and internationally.

The Canadian patents/patent applications that were filed pertain to a variety of Canntab's innovative technologies related to oral dosage formulations of pharmaceutical cannabis, including Sustained Release Cannabinoid Formulations and Sustained Release Cannabinoid Pellets, Immediate Release Cannabidiol Formulations; Modified-Release Multi-Layer Cannabinoid Formulations; Flash-Melt Cannabinoid Formulations; and Bi-layer Cannabinoid Tablets.

These patent applications are part of Canntab's continuing strategy to develop a comprehensive intellectual property portfolio which covers the company's technology and formulations related to pharmaceutical preparations which contain natural or synthetic cannabinoids. Canntab is currently developing a number of products which utilize this technology, including a variety of extended released tablets containing a mixture of THC (Tetrahydrocannabinol) and CBD (Cannabidiol) that may be helpful in the treatment of a number of ailments, such as sleep disorders, post-traumatic stress disorder (PTSD), social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers.

In October, 2022, IP Australia issued patent AU 2018233582 (Australian "Modified Release Multi-Layer Tablet Cannabinoid Formulations"), in force until March 15, 2038. This is Canntab's 4th granted patent and 2nd in Australia. It has a further seven patent applications pending in those countries. One of the seven and one as yet unfiled application will be filed around the world. In addition to patents, the Company also has numerous trademark applications in the United States and Canada that cover four potential trade names for the XR Tablet.

QUARTERLY PERFORMANCE

The following table highlights certain key quarterly financial highlights. Commentary on the selected highlights is included under "Results of Operations" and "Liquidity and Capital Resources".

	Feb-2023 2023 Q2 $	Nov-2022 2023 Q2 $	Aug-2022 2023 Q1 $	May-2022 2022 Q4 $	Feb-2022 2022 Q3 $	Nov-2021 2022 Q2 $	Aug-2021 2022 Q1 $	May-2021 2021 Q4 $	Feb-20 2021 Q $
Balance sheet									
Cash and cash equivalents	16,814	55,316	145,169	691,111	1,501,215	331,746	980,069	1,490,863	1,434,3
Working capital (deficiency)	(2,777,234)	(2,257,194)	(1,574,303)	(1,092,903)	543,648	692,993	1,157,565	1,849,825	2,181,5
Shareholders' equity (deficiency)	(2,159,701)	(1,747,074)	(732,622)	(311,223)	1,055,613	950,728	1,913,360	2,268,758	3,370,4
Income statement									
Tablet sales, net of returns	(22,156)	17,588	38,505	39,540	48,461	170,850	34,511	(843,375)	465,3
Operating expenses	787,650	699,789	388,448	630,372	620,336	557,528	773,518	671,346	418,8
Net loss and comprehensive loss	(412,628)	(1,030,774)	(467,805)	(1,444,284)	(418,338)	(1,222,737)	(603,827)	(2,304,324)	(604,6

RESULTS OF OPERATIONS

Nine months ended February 28, 2023 compared to nine months ended February 28, 2022

The Company had a net loss of $1,911,208 for YTD 2023 compared to $2,244,893 for YTD 2022.

During YTD 2023, the Company recognized revenue, net of estimated return provisions, of $33,936 (YTD 2022 - $256,252) on sales to the Ontario Cannabis Store and online sales.

Operating expenses in YTD 2023 of $787,650 decreased by $1,163,726 compared to YTD 2022 of $1,951,376. The major components of the operating expenses (*defined as total expenses less interest and accretion and non-cash items such as share based compensation, depreciation and amortization, impairment losses and losses on derivatives*) are as follows:

- Employee compensation and benefits were $326,382 in YTD 2023 compared to $776,590 in YTD 2022, a decrease of $450,208. The headcount decreased in YTD 2023 compared to YTD 2022 as the Company reduced its production and operational staffing levels to conserve cash.
- Professional fees decreased by $204,011 from $342,128 in YTD 2022 to $138,117 in YTD 2023 due to higher audit fee accruals and legal fees on the various new affiliate agreements in YTD 2022.
- Consulting fees decreased by $260,257 from $340,172 in YTD 2022 to $79,915 in YTD 2023 for reasons similar to employee compensation and benefits discussed above.
- Marketing and regulatory expenses in YTD 2023 were $108,707 compared to $180,808 in YTD 2022, a decrease of $72,101, largely due to efforts to reduce costs to conserve cash.

- General and administrative expenses in YTD 2023 were $102,729 compared to $166,404 in YTD 2022, a decrease of $63,675, largely due to efforts to reduce costs to conserve cash.

Share based compensation totalled $62,730 in YTD 2023 compared to $372,887 in YTD 2022, a decrease of $310,157 largely due to the timing of recognition of option vesting relative to their issuance dates.

Interest and accretion totalled $615,512 in YTD 2023 compared to $355,899 in YTD 2022, an increase of $259,613. The increase was almost all attributable to accretion expense on the two convertible debenture offerings.

The non-cash gain on derivative liabilities totalled $350,283 in YTD 2023 compared to $794,505 in YTD 2022. The gain was entirely attributable to the convertible debenture offerings completed in December, 2020 and January, 2022. The related derivative liabilities were revalued on a mark-to-market basis to their estimated fair value as at February 28, 2023 to May 31, 2022 (*see further discussion under "Liquidity and Capital Resources" section below).*

Depreciation of plant and equipment and right-of-use assets totalled $359,075 in YTD 2023 compared to $416,983 in YTD 2022, a decrease of $57,908. The decrease was a result of a lower depreciable base in YTD 2023 after accelerated depreciation have been recognized over the past two fiscal years.

The Company recorded impairment provisions in YTD 2023 totalling $286,374, mostly against (i) inventory, to reflect lower inventory turnover, and (ii) plant and equipment, to reflect leasehold improvements no longer available for use after vacating the rental premises in Markham, Ontario.

LIQUIDITY AND CAPITAL RESOURCES

Cash decreased by $674,297 to $16,814 as at February 28, 2023 from $691,111 as at May 31, 2022. The major component of the decrease in cash were the operating expenses in YTD 2023 of $787,650 *(see "Results of Operations" section above).* Working capital deficiency as at February 28, 2023 was $2,777,234 compared to $1,092,903 as at May 31, 2022, an increase of $1,684,331.
The Company has completely restructured its business model going forward through the agreement with BRO *(see discussion under "Agreement with Licensed Producer" section above).* Significant adjustments have been made to its overhead to preserve working capital including

- conversion of production activity to a small batch special order basis, such that all existing sales can be fulfilled from the Company's current inventory
- layoff of all salaried staff
- deferral and/or cancellation of consulting arrangements
- vacating all leased premises
- amendments to the convertible debenture financings of December, 2020 and January, 2022 (under the Agency and Interlender Agreement), including:
    - deferral of effective payment of interest (until at least October, 2023) on both offerings
    - extension of the due date of the December, 2020 financing from December, 2022 to October, 2023

Accounts receivable as at February 28, 2023 of $32,042 (May 31, 2022 - $209,720), a decrease of $177,678, reflecting receipt of previously outstanding HST recoverable after successful completion of a CRA audit.

Inventory as at February 28, 2023 decreased by $202,102 to $287,154, compared to $489,256 at May 31, 2022, following production of 2 commercial batches of 25 mg and 50 mg CBD tablets in 2023 Q1, the first of the XR product line. A further impairment charge of $286,374 was recorded during YTD 2023, bringing the total impairment provision against inventory as of February 28, 2023 to $1,558,165 (May 31, 2022 - $1,271,790). Production activity has been converted to a small batch special order basis, such that all existing sales can be fulfilled from the Company's current inventory.

Accounts payable and accrued liabilities as at February 28, 2023 increased by $244,454 to $1,212,123, compared to $967,669 at May 31, 2022. Under the terms of the MediPharm Memorandum of Understanding dated September 16, 2021, the companies have agreed to settle this obligation for $250,000 (plus applicable HST). This provision has been included in accrued liabilities. Accrued liabilities also includes provisions of $312,433 (May 31, 2022 - $142,158) with respect to unpaid coupon interest owing on both the December, 2020 and January, 2022 debentures.

The carrying value of the December, 2020 debentures payable was accreted to their full face value as at February 28, 2023 of $1,575,000 from $1,300,114 as at May 31, 2022. The related derivative liabilities were revalued on a mark-to-market basis to their estimated fair value as at February 28, 2023 of $Nil compared to $77,229 as at May 31, 2022, an unrealized loss of $(77,229).

The carrying value of the January, 2022 debentures payable was accreted to their carrying value as at February 28, 2023 of $261,060 from $126,204 as at May 31, 2022. The related derivative liabilities were revalued on a mark-to-market basis to their estimated fair value as at February 28, 2023 of $5,061 compared to $278,115 as at May 31, 2022, an unrealized gain of $273,054.

CAPITALIZATION

The Company has common shares and other equity instruments outstanding at each reporting date as follows:

	February 28, 2023	May 31, 2022	Change in reporting period
Common shares	38,909,159	38,909,159	-
Stock options	1,267,926	1,722,926	(455,000)
Special warrants	1,650,000	1,650,000	-
Share purchase warrants	3,843,035	3,843,035	-
Broker compensation warrants	-	47,813	(47,813)
Total equity instruments	45,670,120	46,172,933	(502,813)

The only changes to share capital and other equity instruments during YTD 2023 were the expiries of 455,000 stock options and 47,813 broker warrants. There was no share capital issued, or any stock options, special warrants, broker warrants or share purchase warrants granted, issued, exercised or forfeited during the period.

RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS

As at the date of these unaudited interim condensed consolidated financial statements, the Company has adopted the following new or revised IASB standards effective for annual periods beginning on or after January l, 2022. The Company has determined that the adoption of these new or revised standards has not any impact on these unaudited interim condensed consolidated financial statements.

IAS 16 "Property, Plant and Equipment"

This standard has been amended to prohibit an entity from deducting from the cost of an item of property, plant and equipment any proceeds received from selling items produced while the entity is preparing the asset for its intended use, clarify that an entity is "testing whether the asset is functioning properly" when it assesses the technical and physical performance of the asset and requires certain related disclosures.

IAS 37 "Provisions"

This standard has been amended to clarify that, before a separate provision for an onerous contract is established, an entity recognizes an impairment loss that has occurred on assets used in fulfilling the contract, rather than on assets dedicated to that contract and to clarify the meaning of costs to fulfil a contract.

IFRS 9 "Financial Instruments"

This standard has been amended to address which fees should be included in the 10% test for derecognition of financial liabilities.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

As at the date of authorization of these unaudited interim condensed consolidated financial statements, the IASB has issued the following new or revised standards which are not yet effective. The Company has not yet assessed the impact of these amendments on the unaudited interim condensed consolidated financial statements.

IAS 1, "Presentation of Financial Statements", and IAS 8, "Accounting Policies, Changes in Accounting Estimates and Errors"

This standard has been amended to clarify that liabilities are classified as either current or non-current depending on the rights that exist at the end of the reporting period. Classification is unaffected by the expectations of the entity or events after the reporting date. This amendment also clarifies the meaning of settlement of a liability. This amendment is effective for annual periods beginning on or after January l, 2023.

IAS 12 "Income Taxes"

This standard has been amended to require companies to recognize deferred tax on transactions that, on initial recognition, give rise to equal amounts of taxable and deductible temporary differences. The amendments are effective for annual reporting periods beginning on or after January 1, 2023. This standard has been amended to require companies to recognize deferred tax on transactions that, on initial recognition, give rise to equal amounts of taxable and deductible temporary differences. The amendments are effective for annual reporting periods beginning on or after January 1, 2023.

IAS 8 "Definition of Accounting Estimates"

On February 12, 2021, the IASB issued Definition of Accounting Estimates. The amendments introduce a new definition for accounting estimates, clarifying that they are monetary amounts in the financial statements that are subject to measurement uncertainty. The amendments also clarify the relationship between accounting policies and accounting estimates by specifying that a company develops an accounting estimate to achieve the objective set out by an accounting policy. The amendments are effective for annual periods beginning on or after January 1, 2023.

IAS 1 "Accounting Policies"

On February 12, 2021, the IASB issued amendments to IAS 1 "Presentation of Financial Statements" and an update to IFRS Practice Statement 2 "Making Materiality Judgements" to help companies provide useful accounting policy disclosures.

The key amendments to IAS 1 include a requirement for companies to disclose their material accounting policies rather than their significant accounting policies; clarifying that accounting policies related to immaterial transactions, other events or conditions are themselves immaterial and as such need not be disclosed; and clarifying that not all accounting policies that relate to material transactions, other events or conditions are themselves material to a company's financial statements. The amendments are effective for annual periods beginning on or after January 1, 2023.

CAPITAL RISK MANAGEMENT

The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern and ensure sufficient liquidity in order to develop its resources properties so that it can provide adequate returns for shareholders. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. The Company defines capital as total shareholders' equity.

OFF-BALANCE SHEET ARRANGEMENTS

The Company does not have any off-balance sheet arrangements that have, or are reasonably likely to have, an effect on the results of operations or financial condition of the Company.